Immune Regulatory T Cell Therapy
TYPE 1 DIABETES MELLITUS
As a transplant surgeon, my main focus is on kidney and pancreas transplantation.
I have also developed a special interest in the translational research bringing novel technologies and procedures to the clinical practice.
For the past 9 years, I have been optimizing pancreatic islet transplantation as a minimally invasive procedure for improved glucose control and insulin independence in our patients.
Another objective is to minimize or eliminate the need for toxic anti-rejection medications for a graft protection, to induce immunologic tolerance (the Holy Grail of transplantation) . We have optimized a novel cellular therapy based on ex-vivo expanded T regulatory cells (Tregs).
This therapy can not only benefit transplant patients, but also those with autoimmune disorders like type 1 diabetes, Crohn disease, multiple sclerosis or rheumatoid arthritis.Currently, we are conducting 10 different clinical trials testing novel approaches to improve outcomes in kidney and pancreatic islet transplantation.
For details, see STUDIES link above.
Thank you for your interest in our research.
Piotr Witkowski M.D. Ph.D.